SGAM AI Biotechnology Fund

SGAM AI Biotechnology Fund was a specialized venture capital vehicle managed by SGAM Alternative Investments, the alternative investment arm of Société Générale Asset Management. The fund focused on investing in innovative life science and biotechnology companies across Europe and North America, targeting sectors such as drug discovery, medical devices, and diagnostics. In 2010, following the merger between Société Générale Asset Management and Crédit Agricole Asset Management, the fund's management and assets were integrated into the newly formed Amundi. During its active period, it played a significant role in the European biotech ecosystem by providing equity financing and strategic support to emerging startups. The fund typically targeted early-to-mid-stage companies with high growth potential and proprietary technology platforms.